Management raised Q4 2025 revenue guidance to $21.4 million to $22.4 million and GAAP diluted EPS guidance to $0.43 to $0.47, with non-GAAP diluted EPS of $0.47 to $0.50. For full year 2025, guidance ...

Iradimed picked up an FDA nod for its MRI-compatible intravenous infusion pump system, which enables patients who can’t be disconnected from IV medication to undergo MRI scanning. The company will now ...

Roth MKM has resumed coverage of iRadimed (NASDAQ:IRMD) with a buy rating citing the company's position as the sole provider of MRI-compatible IV pumps. The firm has a $65 price target (~59% upside ...

Iradimed Corporation announced that it has received FDA 510(k) clearance for its next-generation MRidium® 3870 IV Infusion Pump System, making it the only supplier of non-magnetic MRI-compatible ...

Total Revenue-- $21.2 million for the third quarter of 2025, up 16%, driven by MRI compatible IV infusion pump and monitoring system growth. Gross Profit and Margin-- $16.4 million at 78% margin for ...

In a market where major stock indexes are showing mixed results, with the Dow Jones Industrial Average rising and the Nasdaq being pulled down by data-storage shares, investors are keenly observing ...

Pump shipments again led performance in the quarter as our 3860 MRI IV pump grew another 20% year-over-year in Q3. Our MR monitor sales have also continued to impress. I am also pleased to report that ...